Marshall Hyden
Cardiovascular Disease · Omaha, NENPI 1134354368
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. Alnylam Pharmaceuticals Inc. accounts for 69.9% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $2,286, 5.8 times the $395 reported in 2019.
Across 57 payments — averaging $65.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$3K
- Abbott$395
- Medtronic$276
- Pfizer$171
- AstraZeneca$125
- Novartis$81
- plus $72 from 3 others
What the payments were for
- Travel & lodging$1,67545%
- Food & beverage$2,00954%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 15 | $2,607 |
| Abbott | 23 | $395 |
| Medtronic | 4 | $276 |
| Pfizer | 5 | $171 |
| AstraZeneca | 3 | $125 |
| Novartis | 4 | $81 |
| Inspire Medical Systems, Inc. | 1 | $37 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMVUTTRA$2,057
- HeartWare HVAD$138
- VYNDAQEL$108
How this compares
$3,728 in reported general payments places this provider in the 65th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 65 | $1,489,717 |
| VyndaqelTafamidis Meglumine | 11 | $270,381 |
| EntrestoSacubitril/Valsartan | 101 | $126,154 |
| EliquisApixaban | 60 | $57,296 |
| JardianceEmpagliflozin | 53 | $49,853 |
| FarxigaDapagliflozin Propanediol | 32 | $32,662 |
| Sirolimus | 17 | $16,103 |
| Repatha SureclickEvolocumab | 12 | $8,823 |
| Tacrolimus | 57 | $7,408 |
| Mycophenolate Mofetil | 21 | $2,094 |
| Metoprolol Succinate | 111 | $1,898 |
| Potassium Chloride | 52 | $1,587 |
| Torsemide | 48 | $1,564 |
| Eplerenone | 14 | $966 |
| Rosuvastatin Calcium | 57 | $732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $171 | $1,817,394136 claims |
| NovartisEntresto | $81 | $126,154101 claims |
| AstraZenecaFarxiga | $125 | $32,66232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$945K
- Jeffrey CarstensOmaha$124K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Edward OlearyOmaha$36K
- Faris KhanOmaha$17K
- Michael PetersOmaha$13K
- Thomas PorterOmaha$11K
- Gregory PavlidesOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.